Case Report: An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the abdominal wall
{{output}}
Pancreatic ductal adenocarcinoma (PDAC) is a difficult-to-treat cancer with a 5-year survival rate of only 13%. Intense chemotherapies are needed to control the disease. Surgical resection, if possible, is the only curative approach. However, recurrence rates ... ...
